Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Nuvalent, Inc. (NASDAQ:NUVL) have been assigned an average recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and fifteen have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $138.6667.

A number of equities analysts have recently issued reports on NUVL shares. UBS Group reiterated a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. JPMorgan Chase & Co. dropped their target price on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Truist Financial set a $140.00 target price on Nuvalent in a research note on Monday, November 24th. Cantor Fitzgerald increased their price target on shares of Nuvalent from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd.

Insider Activity at Nuvalent

In related news, insider Deborah Ann Miller sold 14,300 shares of Nuvalent stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $110.16, for a total value of $1,575,288.00. Following the transaction, the insider owned 59,634 shares in the company, valued at $6,569,281.44. This trade represents a 19.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alexandra Balcom sold 4,236 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $97.32, for a total transaction of $412,247.52. Following the completion of the sale, the chief financial officer directly owned 84,914 shares of the company’s stock, valued at $8,263,830.48. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 69,379 shares of company stock worth $6,940,982 in the last 90 days. Corporate insiders own 10.20% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent in the 3rd quarter worth approximately $38,000. Eastern Bank bought a new stake in Nuvalent in the third quarter valued at approximately $52,000. NBC Securities Inc. purchased a new stake in shares of Nuvalent during the fourth quarter valued at approximately $125,000. Finally, KBC Group NV boosted its stake in shares of Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after purchasing an additional 297 shares during the period. Institutional investors own 97.26% of the company’s stock.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL opened at $96.43 on Tuesday. The firm has a market capitalization of $7.58 billion, a PE ratio of -16.48 and a beta of 1.32. Nuvalent has a 52-week low of $55.53 and a 52-week high of $113.01. The firm has a fifty day moving average of $102.48 and a 200 day moving average of $97.93.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.